235 related articles for article (PubMed ID: 10095448)
41. [Relationship of PTEN, Mdm2 and p53 expression in astrocytoma].
Zhong XY; Sun YH; Chen YX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):478-81. PubMed ID: 14575575
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of MDM2 in acute childhood lymphoblastic leukemia.
Gustafsson B; Stål O; Gustafsson B
Pediatr Hematol Oncol; 1998; 15(6):519-26. PubMed ID: 9842645
[TBL] [Abstract][Full Text] [Related]
43. MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma.
Reid AH; Tsai MM; Venzon DJ; Wright CF; Lack EE; O'Leary TJ
Diagn Mol Pathol; 1996 Mar; 5(1):65-73. PubMed ID: 8919547
[TBL] [Abstract][Full Text] [Related]
44. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
45. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
Foulkes WD; Stamp GW; Afzal S; Lalani N; McFarlane CP; Trowsdale J; Campbell IG
Br J Cancer; 1995 Oct; 72(4):883-8. PubMed ID: 7547235
[TBL] [Abstract][Full Text] [Related]
46. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
[TBL] [Abstract][Full Text] [Related]
47. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
48. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
49. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
Patel H; Polanco-Echeverry G; Segditsas S; Volikos E; McCart A; Lai C; Guenther T; Zaitoun A; Sieber O; Ilyas M; Northover J; Silver A
Int J Cancer; 2007 Dec; 121(12):2668-73. PubMed ID: 17721920
[TBL] [Abstract][Full Text] [Related]
50. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
[TBL] [Abstract][Full Text] [Related]
51. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
[TBL] [Abstract][Full Text] [Related]
52. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
[TBL] [Abstract][Full Text] [Related]
53. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
Davies AJ; Lee AM; Taylor C; Clear AJ; Goff LK; Iqbal S; Cuthbert-Heavens D; Calaminici M; Norton AJ; Lister TA; Fitzgibbon J
Leukemia; 2005 Aug; 19(8):1459-65. PubMed ID: 15902285
[TBL] [Abstract][Full Text] [Related]
54. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
[TBL] [Abstract][Full Text] [Related]
55. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
[TBL] [Abstract][Full Text] [Related]
56. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
57. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
58. Distinct MDM2 and P14ARF expression and centrosome amplification in well-differentiated liposarcomas.
Perucca-Lostanlen D; Rostagno P; Grosgeorge J; Marcié S; Gaudray P; Turc-Carel C
Genes Chromosomes Cancer; 2004 Feb; 39(2):99-109. PubMed ID: 14695989
[TBL] [Abstract][Full Text] [Related]
59. Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.
Pykett MJ; Landers J; George DL
J Neurooncol; 1997 Mar; 32(1):39-44. PubMed ID: 9049861
[TBL] [Abstract][Full Text] [Related]
60. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
